US pharmaceutical company Novavax said its Covid-19 vaccine has an overall efficacy of 90.4 percent against the coronavirus.
Based on a study with 29,960 participants across 119 sites in the US, the company said its two-dose vaccine demonstrated 100 percent protection against moderate and severe disease.
Against some coronavirus variants, which represented 82 percent of the cases, the vaccine efficacy was 93.2 percent.
The president of Novavax’s Research and Development said, “These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent Covid-19 amid ongoing genetic evolution of the virus.”
The company said it plans to file for regulatory authorizations of the vaccine in the third quarter of this year.
It estimates to reach a manufacturing capacity of 100 million doses per month by the end of the third quarter, and 150 million doses per month by the end of the fourth quarter of 2021.